Chlorthalidone
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Chlorthalidone: From Hypertension to Primary Hereditary Glaucoma
One-Sentence Summary
Chlorthalidone is a thiazide-like diuretic. It is generally used for hypertension and fluid retention, although the provided license records do not state an indication. The TxGNN model predicts it may be effective for primary hereditary glaucoma, but 0 clinical trials and 0 publications support this direction. The prediction rests on the model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Hypertension and edema (general pharmacology; the license records list no indication text) |
| Predicted New Indication | Primary hereditary glaucoma |
| TxGNN Prediction Score | 99.92% (model rank 2719) |
| Evidence Level | L5 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 20 (generic ANDA approvals) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Chlorthalidone is a thiazide-like diuretic, and its efficacy in blood pressure control and fluid removal is well established. Any link to glaucoma is therefore speculative.
One possible connection is the weak carbonic anhydrase-related and fluid-shifting effects of thiazide-like diuretics, which might influence aqueous humor dynamics. However, primary hereditary glaucoma is largely developmental or genetic (for example, CYP1B1-related). A systemic diuretic is unlikely to address the underlying cause.
The high score (0.999) most likely reflects patterns in the knowledge graph rather than a validated pharmacological rationale.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ANDA211063 | Chlorthalidone (Chartwell RX, LLC) | Tablet | Not listed in the record |
| ANDA213412 | Chlorthalidone (Preferred Pharmaceuticals Inc.) | Tablet | Not listed in the record |
| ANDA212878 | Chlorthalidone (Bryant Ranch Prepack) | Tablet | Not listed in the record |
| ANDA214129 | Chlorthalidone (Ajanta Pharma USA Inc.) | Tablet | Not listed in the record |
| ANDA213412 | Chlorthalidone (Bryant Ranch Prepack) | Tablet | Not listed in the record |
All products are oral tablets. Five of the 20 licenses are shown.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The only support for this indication is a model score. No trials or publications were found, the mechanism is speculative, and hereditary glaucoma is mainly a genetic or developmental condition that a diuretic is unlikely to treat.
To proceed, the following is needed:
- The package insert (warnings, contraindications, approved indications)
- Mechanism of action data from DrugBank
- A targeted literature search on thiazide-like diuretics and intraocular pressure or aqueous humor dynamics
- Review by an ophthalmology expert on whether any plausible mechanism exists
Other candidates in this evidence pack: Among the other predicted indications, chronic pulmonary heart disease (rank 8) has the strongest evidence, at L3. A 1967 report describes chlorthalidone in congestive heart failure due to chronic cor pulmonale. That report’s design is unverified, and the one related registered trial does not test chlorthalidone. It may be a better candidate to prioritize than glaucoma.
This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any application.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.